keyword
MENU ▼
Read by QxMD icon Read
search

LDL Particle number

keyword
https://www.readbyqxmd.com/read/28078862/a-placebo-controlled-trial-of-a-proprietary-lipid-lowering-nutraceutical-supplement-in-the-management-of-dyslipidemia
#1
M Houston, R Rountree, J Lamb, S Phipps, S Meng, B Zhang
There is an ever growing emergence in the popularity of patient-driven care. As this health and wellness model grows, inquiries into diet, lifestyle, and supplemental approaches will continue to become a focal point for the healthcare consumer. Because of this, the aim of this study is to determine the tolerability, and overall effectiveness of a proprietary multi-ingredient lipid-lowering supplement in subjects with dyslipidemia. Forty participants were recruited for a single-center, double-blind randomized, placebocontrolled trial...
October 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28062489/lipoprotein-a-mass-levels-increase-significantly-according-to-apoe-genotype-an-analysis-of-431%C3%A2-239-patients
#2
Patrick M Moriarty, Stephen A Varvel, Philip L S M Gordts, Joseph P McConnell, Sotirios Tsimikas
OBJECTIVE: Lipoprotein(a) [Lp(a)] levels are genetically determined by hepatocyte apolipoprotein(a) synthesis, but catabolic pathways also influence circulating levels. APOE genotypes have different affinities for the low-density lipoprotein (LDL) receptor and LDL-related protein-1, with ε2 having the weakest binding to LDL receptor at <2% relative to ε3 and ε4. APPROACH AND RESULTS: APOE genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4), Lp(a) mass, directly measured Lp(a)-cholesterol levels, and a variety of apoB-related lipoproteins were measured in 431 239 patients...
January 5, 2017: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/28053201/evidence-that-supports-the-prescription-of-low-carbohydrate-high-fat-diets-a-narrative-review
#3
Timothy David Noakes, Johann Windt
Low-carbohydrate high-fat (LCHF) diets are a highly contentious current topic in nutrition. This narrative review aims to provide clinicians with a broad overview of the effects of LCHF diets on body weight, glycaemic control and cardiovascular risk factors while addressing some common concerns and misconceptions. Blood total cholesterol and LDL-cholesterol concentrations show a variable, highly individual response to LCHF diets, and should be monitored in patients adhering to this diet. In contrast, available evidence from clinical and preclinical studies indicates that LCHF diets consistently improve all other markers of cardiovascular risk-lowering elevated blood glucose, insulin, triglyceride, ApoB and saturated fat (especially palmitoleic acid) concentrations, reducing small dense LDL particle numbers, glycated haemoglobin (HbA1c) levels, blood pressure and body weight while increasing low HDL-cholesterol concentrations and reversing non-alcoholic fatty liver disease (NAFLD)...
January 2017: British Journal of Sports Medicine
https://www.readbyqxmd.com/read/28038378/the-causal-effects-of-alcohol-on-lipoprotein-subfraction-and-triglyceride-levels-using-a-mendelian-randomization-analysis-the-nagahama-study
#4
Yasuharu Tabara, Hidenori Arai, Yuhko Hirao, Yoshimitsu Takahashi, Kazuya Setoh, Takahisa Kawaguchi, Shinji Kosugi, Yasuki Ito, Takeo Nakayama, Fumihiko Matsuda
BACKGROUND: Light-to-moderate alcohol consumption may increase circulating high-density lipoprotein cholesterol (HDL-C) levels and decrease low-density lipoprotein cholesterol (LDL-C) levels. However, the effect of alcohol on biologically important lipoprotein subfractions remains largely unknown. Here we aimed to clarify the effects of alcohol on lipoprotein subfractions using a Mendelian randomization analysis. METHODS: The study subjects consisted of 8364 general Japanese individuals...
December 22, 2016: Atherosclerosis
https://www.readbyqxmd.com/read/28029752/effects-of-baricitinib-on-lipid-apolipoprotein-and-lipoprotein-particle-profiles-in-a-phase-2b-study-in-patients-with-active-rheumatoid-arthritis
#5
Joel Kremer, Mark C Genovese, Edward Keystone, Peter C Taylor, Steven H Zuckerman, Giacomo Ruotolo, Douglas E Schlichting, Victoria L Crotzer, Eric Nantz, Scott D Beattie, William L Macias
Objective To assess the effects of baricitinib on lipid profile in patients with moderate-to-severe rheumatoid arthritis. Methods Once-daily baricitinib (1, 2, 4, or 8-mg) or placebo was studied in 301 randomized patients. Changes in lipid profile, particle size, and number were assessed at weeks 12/24; associations with clinical efficacy were evaluated. Apolipoproteins were assessed at weeks 4/12 for the placebo, and 4- and 8-mg baricitinib groups. Results Baricitinib treatment resulted in dose-dependent increases by week 12 in serum lipids (low-density lipoprotein cholesterol [LDL-C]: 3...
December 28, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28025677/pcsk9-inhibition-the-dawn-of-a-new-age-in-cholesterol-lowering
#6
REVIEW
David Preiss, Marion Mafham
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating enzyme of hepatic origin that plays a key role in LDL receptor turnover. Genetic studies have confirmed that individuals with gain-of-function PCSK9 mutations have increased PCSK9 activity, elevated LDL-cholesterol levels and a severe form of familial hypercholesterolaemia. Those with variants leading to reduced PCSK9 have lower LDL-cholesterol levels and a reduced risk of coronary heart disease, and this has led to the development of various strategies aimed at reducing circulating PCSK9...
December 26, 2016: Diabetologia
https://www.readbyqxmd.com/read/27927162/use-of-low-density-lipoprotein-particle-number-levels-as-an-aid-in-statin-treatment-decisions-for-intermediate-risk-patients-a-cost-effectiveness-analysis
#7
Dov Shiffman, Andre R Arellano, Michael P Caulfield, Judy Z Louie, Lance A Bare, James J Devlin, Olle Melander
BACKGROUND: The 2013 ACC/AHA guideline recommended either no statin therapy or moderate-intensity statin therapy (MST) for intermediate risk patients-those with 5-7.5% 10-year risk and without cardiovascular disease (CVD), hypercholesterolemia or diabetes. The guideline further suggested that the therapy choice be based on patient-clinician discussions of risks and benefits. Since low-density lipoprotein particle (LDL-P) levels were reported to be associated with CVD independently of traditional risk factors in intermediate and low risk patients, we investigated the cost-effectiveness of using LDL-P levels to identify intermediate risk patients likely to benefit from initiating or intensifying statin therapy...
December 7, 2016: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/27903361/-evaluation-of-health-effect-among-occupational-population-exposed-to-nano-titanium-dioxide-a-cross-sectional-study
#8
H D Xu, J W Zhou, S C Tang, F L Kong, X W Li, Z L Shen, L Yan, Z J Chen, L Zhao, G Jia, J Zhang
Objective: To characterize the health effects of nano-titanium dioxide exposure in an occupational cohort. Methods: Eighty-five male employees of a nano-titanium dioxide manufacturing enterprise in Shandong Province were evaluated in September 2014. Forty-four were exposed to nano-titanium dioxide (exposure group), and 41 were not exposed to nano-titanium dioxide (control group). We collected employees' basic information, smoking and drinking history, previous medical history, family history, and occupational history...
November 6, 2016: Zhonghua Yu Fang Yi Xue za Zhi [Chinese Journal of Preventive Medicine]
https://www.readbyqxmd.com/read/27887691/cost-effectiveness-of-achieving-targets-of-low-density-lipoprotein-particle-number-versus-low-density-lipoprotein-cholesterol-level
#9
Michael Grabner, Deborah A Winegar, Rajeshwari S Punekar, Ralph A Quimbo, Mark J Cziraky, William C Cromwell
A recent analysis of a commercially insured US population found fewer cardiovascular disease (CVD) events in high-risk patients attaining low levels of low-density lipoprotein (LDL), as measured by LDL particle number (LDL-P) versus low LDL cholesterol (LDL-C). Here, we investigated the cost effectiveness of LDL-lowering therapy guided by LDL-P. Patients were selected from the HealthCore Integrated Research Database and followed for 12 to 36 months. Patients who achieved LDL-P <1,000 nmol/l were placed into the LDL-P cohort, whereas those without LDL-P tests, but who achieved LDL-C <100 mg/dl, were placed into the LDL-C cohort...
February 1, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/27866534/-dihydrotestosterone-inhibits-foam-cell-formation-via-a-lectin-like-ox-low-density-lipoprotein-receptor-mediated-mechanism-in-j774-1-cell-line
#10
Y Qiu, H D Hu, B Q Hu, X Y Chen, P Y Xu, L Cui, P Li, C Liu, L Li
Objective: To investigate the effect of dihydrotestosterone (DHT) on lectin-like ox- low-density lipoprotein (LDL) receptor(LOX-1)expression and foam cell formation in the female macrophage cell line J774.1. Methods: In cultured J774.1 cells, after pretreated with DHT at concentrations of 1×10(-9) mol/L and 1×10(-8) mol/L, ox-LDL-induced LOX-1 expression and foam cell formation were investigated by quantitative real-time PCR, Western blotting, and oil-red O staining. Results: DHT at concentrations of 1×10(-9) mol/L and 1×10(-8) mol/L inhibited ox-LDL-induced LOX-1 mRNA (2...
November 15, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/27816804/persistent-changes-in-lipoprotein-lipids-after-a-single-infusion-of-ascending-doses-of-mdco-216-apoa-imilano-popc-in-healthy-volunteers-and-stable-coronary-artery-disease-patients
#11
Herman J Kempen, Monica Gomaraschi, Sara Simonelli, Laura Calabresi, Matthijs Moerland, James Otvos, Elias Jeyarajah, David Kallend, Peter L J Wijngaard
BACKGROUND AND AIMS: Effects of single ascending doses of MDCO-216 on plasma lipid and lipoprotein levels were assessed in human healthy volunteers and in patients with stable coronary artery disease (CAD). METHODS: MDCO-216 was infused at a single dose of 5, 10, 20, 30 or 40 mg/kg over 2 h and blood was collected at 2, 4, 8, 24, 48, 168 and 720 h after start of infusion (ASOI). Lipoprotein lipids were assessed by FLPC and by 1H NMR. RESULTS: Plasma concentrations of free cholesterol (FC) displayed a rapid and dose-dependent rise, peaking at 8 h, but remaining above baseline until 48 h ASOI, whereas levels of esterified cholesterol (CE) increased at lower doses but not at higher doses, and even decreased below baseline at the highest dose...
December 2016: Atherosclerosis
https://www.readbyqxmd.com/read/27784733/comprehensive-analysis-of-established-dyslipidemia-associated-loci-in-the-diabetes-prevention-program
#12
Tibor V Varga, Alexandra H Winters, Kathleen A Jablonski, Edward S Horton, Prajakta Khare-Ranade, William C Knowler, Santica M Marcovina, Frida Renström, Karol E Watson, Ronald Goldberg, José C Florez, Toni I Pollin, Paul W Franks
BACKGROUND: We assessed whether 234 established dyslipidemia-associated loci modify the effects of metformin treatment and lifestyle intervention (versus placebo control) on lipid and lipid subfraction levels in the Diabetes Prevention Program randomized controlled trial. METHODS AND RESULTS: We tested gene treatment interactions in relation to baseline-adjusted follow-up blood lipid concentrations (high-density lipoprotein [HDL] and low-density lipoprotein-cholesterol, total cholesterol, and triglycerides) and lipoprotein subfraction particle concentrations and size in 2993 participants with pre-diabetes...
December 2016: Circulation. Cardiovascular Genetics
https://www.readbyqxmd.com/read/27740536/treatment-of-hiv-infection-with-a-raltegravir-based-regimen-increases-ldl-levels-but-improves-hdl-cholesterol-efflux-capacity
#13
Nicholas T Funderburg, Dihua Xu, Martin P Playford, Aditya A Joshi, Adriana Andrade, Daniel R Kuritzkes, Michael M Lederman, Nehal N Mehta
BACKGROUND: Persons infected with HIV often have altered lipid profiles that may be affected by antiretroviral therapies (ART). Traditional lipid measurements may be insufficient to assess cardiovascular disease (CVD) risk in this population. METHODS: We report results from 39 ART-naïve participants in a substudy of A5248, a single-arm study of raltegravir (RAL), emtricitabine/tenofovir administration. Samples were collected at baseline, 12, 24, and 48 weeks after ART initiation...
October 14, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27736980/patients-with-rheumatoid-arthritis-show-altered-lipoprotein-profiles-with-dysfunctional-high-density-lipoproteins-that-can-exacerbate-inflammatory-and-atherogenic-process
#14
Jae-Yong Kim, Eun-Young Lee, Jin Kyun Park, Yeong Wook Song, Jae-Ryong Kim, Kyung-Hyun Cho
OBJECTIVE: In order to identify putative biomarkers in lipoprotein, we compared lipid and lipoprotein properties between rheumatoid arthritis (RA) patients and control with similar age. METHODS: We analyzed four classes of lipoproteins (VLDL, LDL, HDL2, HDL3) from both male (n = 8, 69±4 year-old) and female (n = 25, 53±7 year-old) rheumatoid arthritis (RA) patients as well as controls with similar age (n = 13). RESULTS: Although RA group showed normal levels of total cholesterol (TC), low-density lipoprotein (LDL)-cholesterol, and glucose, however, the RA group showed significantly reduced high-density lipoprotein (HDL)-C level and ratio of HDL-C/TC...
2016: PloS One
https://www.readbyqxmd.com/read/27729386/higher-chylomicron-remnants-and-ldl-particle-numbers-associate-with-cd36-snps-and-dna-methylation-sites-that-reduce-cd36
#15
Latisha Love-Gregory, Aldi T Kraja, Fiona Allum, Stella Aslibekyan, Åsa K Hedman, Yanan Duan, Ingrid B Borecki, Donna K Arnett, Mark I McCarthy, Panos Deloukas, Jose M Ordovas, Paul N Hopkins, Elin Grundberg, Nada A Abumrad
Cluster of differentiation 36 (CD36) variants influence fasting lipids and risk of metabolic syndrome, but their impact on postprandial lipids, an independent risk factor for cardiovascular disease, is unclear. We determined the effects of SNPs within a ∼410 kb region encompassing CD36 and its proximal and distal promoters on chylomicron (CM) remnants and LDL particles at fasting and at 3.5 and 6 h following a high-fat meal (Genetics of Lipid Lowering Drugs and Diet Network study, n = 1,117). Five promoter variants associated with CMs, four with delayed TG clearance and five with LDL particle number...
December 2016: Journal of Lipid Research
https://www.readbyqxmd.com/read/27678443/an-evidence-based-analysis-of-the-national-lipid-association-recommendations-concerning-non-hdl-c-and-apob
#16
Allan D Sniderman, Peter P Toth, George Thanassoulis, Curt D Furberg
BACKGROUND: The National Lipid Association (NLA) selected non-HDL-C as its prime index of the cardiovascular risk associated with the apoB lipoproteins. ApoB was recommended only as an optional secondary target after low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (HDL-C) targets were achieved. OBJECTIVE: The aims of this analysis were to determine whether (1) all relevant uses of apoB were considered by the NLA; (2) all the relevant evidence was considered by the NLA panel; and (3) all the evidence that was considered was interpreted correctly...
September 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27596163/differences-in-glyca-and-lipoprotein-particle-parameters-may-help-distinguish-acute-kawasaki-disease-from-other-febrile-illnesses-in-children
#17
Margery A Connelly, Chisato Shimizu, Deborah A Winegar, Irina Shalaurova, Ray Pourfarzib, James D Otvos, John T Kanegaye, Adriana H Tremoulet, Jane C Burns
BACKGROUND: Glycosylation patterns of serum proteins, such as α1-acid glycoprotein, are modified during an acute phase reaction. The response of acute Kawasaki disease (KD) patients to IVIG treatment has been linked to sialic acid levels on native IgG, suggesting that protein glycosylation patterns vary during the immune response in acute KD. Additionally, the distribution and function of lipoprotein particles are altered during inflammation. Therefore, the aim of this study was to explore the potential for GlycA, a marker of protein glycosylation, and the lipoprotein particle profile to distinguish pediatric patients with acute KD from those with other febrile illnesses...
September 5, 2016: BMC Pediatrics
https://www.readbyqxmd.com/read/27581580/compared-with-powdered-lutein-a-lutein-nanoemulsion-increases-plasma-and-liver-lutein-protects-against-hepatic-steatosis-and-affects-lipoprotein-metabolism-in-guinea-pigs
#18
Ana Gabriela Murillo, David Aguilar, Gregory H Norris, Diana M DiMarco, Amanda Missimer, Siqi Hu, Joan A Smyth, Sarah Gannon, Christopher N Blesso, Yangchao Luo, Maria Luz Fernandez
BACKGROUND: It is not clear how oil-in-water nanoemulsions of lutein may affect bioavailability and consequently alter lipoprotein metabolism, oxidative stress, and inflammation. OBJECTIVE: The bioavailability as well as effects of a powdered lutein (PL) and an oil-in-water lutein nanoemulsion (NANO; particle size: 254.2 nm; polydispersity index: 0.29; and ζ-potential: -65 mV) on metabolic variables in liver, plasma, and adipose tissue in a guinea pig model of hepatic steatosis were evaluated...
October 2016: Journal of Nutrition
https://www.readbyqxmd.com/read/27575649/mendelian-randomization-analysis-in-three-japanese-populations-supports-a-causal-role-of-alcohol-consumption-in-lowering-low-density-lipid-cholesterol-levels-and-particle-numbers
#19
Yasuharu Tabara, Hirotsugu Ueshima, Naoyuki Takashima, Takashi Hisamatsu, Akira Fujiyoshi, Maryam Zaid, Masaki Sumi, Katsuhiko Kohara, Tetsuro Miki, Katsuyuki Miura
BACKGROUND AND AIMS: While alcohol consumption is known to increase plasma high-density lipoprotein (HDL) cholesterol levels, its relationship with low-density lipoprotein (LDL) cholesterol levels is unclear. Aldehyde dehydrogenase 2 (ALDH2) is a rate-controlling enzyme in alcohol metabolism, but a large number of Japanese people have the inactive allele. Here, we conducted a Mendelian randomization analysis using the ALDH2 genotype to clarify a causal role of alcohol on circulating cholesterol levels and lipoprotein particle numbers...
August 24, 2016: Atherosclerosis
https://www.readbyqxmd.com/read/27552305/role-of-lipoproteins-and-proprotein-convertase-subtilisin-kexin-type-9-in-endotoxin-clearance-in-sepsis
#20
Keith R Walley
PURPOSE OF REVIEW: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a recent high-impact cardiovascular intervention aimed at reducing low-density lipoprotein (LDL) cholesterol levels. Notably, pathogen lipids are also carried in lipoprotein particles and are cleared by hepatocyte LDL receptors. Therefore, the role of PCSK9 in sepsis is reviewed. RECENT FINDINGS: Endogenous PCSK9 decreases clearance of LDL cholesterol by decreasing the number of LDL receptors on hepatocytes...
October 2016: Current Opinion in Critical Care
keyword
keyword
36497
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"